D. Boral Capital Reiterates “Buy” Rating for Imunon (NASDAQ:IMNN)

D. Boral Capital reissued their buy rating on shares of Imunon (NASDAQ:IMNN) in a research note issued to investors on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $29.00 price objective on the stock.

Other research analysts have also issued research reports about the stock. EF Hutton Acquisition Co. I upgraded shares of Imunon to a “strong-buy” rating in a research note on Monday, September 23rd. HC Wainwright reduced their price target on Imunon from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Monday, November 11th.

Imunon Price Performance

IMNN opened at $0.90 on Tuesday. The firm has a market capitalization of $13.04 million, a PE ratio of -0.48 and a beta of 2.12. The business’s 50-day moving average is $0.90 and its two-hundred day moving average is $1.11. Imunon has a 1 year low of $0.48 and a 1 year high of $3.65.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.